Nintedanib for treating progressive fibrosing interstitial lung diseases

Lancet Respir Med. 2021 Dec;9(12):e116-e117. doi: 10.1016/S2213-2600(21)00517-8. Epub 2021 Nov 18.

Authors

Amanda I Adler¹, Yelan Guo², Aminata Thiam², Nicole Elliot², Sanjeev Patel³

Affiliations

¹ Diabetes Trial Unit, Biomedical Research Centre, Oxford Centre for Diabetes Endocrinology and Metabolism, Oxford, UK. Electronic address: Amanda.adler@dtu.ox.ac.uk.
² National Institute for Health and Care Excellence, Manchester, UK.
³ Department of Rheumatology, Kings College Hospital, London, UK.

PMID: 34801109
DOI: 10.1016/S2213-2600(21)00517-8

No abstract available

MeSH terms

Disease Progression
Humans
Indoles* / therapeutic use
Lung Diseases, Interstitial* / drug therapy

Substances

Indoles
nintedanib